GlobeNewswire Inc | May 24, 2021 04:05PM EDT

May 24, 2021

BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:

The Jefferies Virtual Healthcare Conference, taking place June 1-4, 2021: Interim Chief Executive Officer Heidi Hagen and Chief Medical Officer Raffaele Baffa will participate in a fireside chat on June 4 at 1pm ET.

The Virtual Raymond James Human Health Innovations Conference, taking place June 21-23, 2021: Interim Chief Executive Officer Heidi Hagen will participate in a fireside chat on June 22 at 2:40pm ET.

Webcasts of the conference presentations will be available using links that will be posted on the Ziopharm website, www.ziopharm.com, in the Investor section.

AboutZiopharm Oncology, Inc.Ziopharm is a clinical stage biotech, developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with cancer each year. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, and a rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with leading public and private institutions including theNational Cancer Institute and the University of Texas MD Anderson Cancer Center. For more information, please visitwww.ziopharm.com.

Investor Relations Contact:Adam D. Levy, Ph.D., MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E:alevy@ziopharm.com